AmgenAMGN
About: Amgen is a leader in biotechnology-based human therapeutics. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). The 2023 Horizon acquisition brings several rare-disease drugs, including thyroid eye disease drug Tepezza. Amgen also has a growing biosimilar portfolio.
Employees: 26,700
Fund manager confidence
Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)
21% more first-time investments, than exits
New positions opened: 284 | Existing positions closed: 235
1.27% more ownership
Funds ownership: 76.41% [Q3] → 77.68% (+1.27%) [Q4]
9% more call options, than puts
Call options by funds: $1.98B | Put options by funds: $1.82B
0% less funds holding
Funds holding: 2,788 [Q3] → 2,776 (-12) [Q4]
5% less repeat investments, than reductions
Existing positions increased: 1,059 | Existing positions reduced: 1,110
15% less capital invested
Capital invested by funds: $132B [Q3] → $112B (-$19.8B) [Q4]
46% less funds holding in top 10
Funds holding in top 10: 69 [Q3] → 37 (-32) [Q4]
Research analyst outlook
6 Wall Street Analysts provided 1 year price targets over the past 3 months
6 analyst ratings
B of A Securities Tim Anderson 36% 1-year accuracy 5 / 14 met price target | 4%downside $294 | Underperform Maintained | 5 Mar 2025 |
Piper Sandler David Amsellem 55% 1-year accuracy 18 / 33 met price target | 7%upside $329 | Overweight Maintained | 10 Feb 2025 |
Citigroup Geoff Meacham 56% 1-year accuracy 19 / 34 met price target | 4%downside $295 | Neutral Maintained | 28 Jan 2025 |
RBC Capital Gregory Renza 32% 1-year accuracy 24 / 75 met price target | 6%upside $324 | Outperform Reiterated | 24 Jan 2025 |
Wells Fargo Mohit Bansal 44% 1-year accuracy 12 / 27 met price target | 9%downside $280 | Equal-Weight Maintained | 10 Jan 2025 |
Financial journalist opinion
Based on 38 articles about AMGN published over the past 30 days
